An observational study in Malignancy-induced Pelvic Pain, sponsored by University of Arizona. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-31.
Sponsored by University of Arizona · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.
Among the 152 studies in Pelvic Pain with a site in United States, this one is the 26th largest by planned enrollment of the 28 observational ones that give a count, is one of 7 that started in 2023, is one of 28 observational ones, reaches primary completion later than 7 of the 39 other live ones, and was the 120th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 8–18
Oregon Health and Science University · Sites in United States
Ages 18–45 · Women only
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 100 across 84 observational studies indexed under Pelvic Pain.
Median enrollment 50 across the 124 interventional studies, 104 across the 28 observational. Of the 96 that completed or were terminated, 35 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 152 have an industry lead sponsor. The 10 most frequent:
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
University of Arizona has 1 study filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
16 of the studies in Pelvic Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06110065University of ArizonaCT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain | 2026-11 |
| NCT05354869University of California, Los AngelesTransvaginal Electrical Stimulation for Myofascial Pelvic Pain | 2026-12 |
| NCT03794466University of Kansas Medical CenterQuantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization | 2026-12-31 |
| NCT06083597Weill Medical College of Cornell UniversityDevelopment of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain | 2026-12-31 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 152 studies in Pelvic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We want to study if a new treatment called "CT-guided bilateral pudendal nerve cryoneurolysis" can help people with severe and long-lasting pain in the pelvic area caused by cancer. We will closely follow and observe patients who undergo this treatment to see if it works well, what results it gives, and if there are any problems or side effects. "Percutaneous image-guided cryoneurolysis" involves using very cold temperatures to treat the nerves causing the pain. This method has been found to provide longer pain relief compared to injections or catheters, and it also has a lower risk of certain complications.
We are conducting a study to assess the effectiveness of two different treatments for severe and persistent pelvic pain caused by cancer. The first treatment, known as "CT-guided bilateral pudendal nerve cryoneurolysis," involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals. By closely monitoring patients who receive this treatment, we aim to evaluate its efficacy, outcomes, and potential side effects.
On the other hand, the second treatment approach, referred to as "Percutaneous image-guided cryoneurolysis," focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications. Through our study, we seek to gain insights into the effectiveness and safety of both treatment methods, enhancing our understanding of how to address the challenging issue of cancer-related pelvic pain.
The study will enroll patients who are dealing with severe and persistent pelvic pain from cancer. All patients will undergo the CT-guided bilateral pudendal nerve cryoneurolysis first type of treatment and if it is not effective in relieving the pain, they will be offered to undergo the second treatment called Percutaneous image-guided cryoneurolysis.
Both of these treatments are done as standard of care. This research study will not alter standard of care. Subjects will only be enrolled into this study if they are already undergoing CT-guided bilateral pudendal nerve cryoneurolysis followed up with Percutaneous image-guided cryoneurolysis, as needed. This is a prospective study of these two treatments following patient outcomes.
Interventional Radiology Oncology clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Those already scheduled for a CT-guided bilateral pudendal nerve cryoneurolysis as standard of care Age ≥18 years old Active or history of pelvic cancer Poor pelvic pain control with current therapy (pain from cancer malignancy) Pain in distribution of the pudendal (genital) nerves from cancer malignancy
Exclusion Criteria:
Pain in distribution of the pudendal nerves from nonmalignant etiology Patients with pain from other medical conditions besides cancer/cancer will not be included (cancer-related pain from cancer malignancy in the genital region is considered).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CT-guided Pudendal Nerve Cryoneurolysis · Drug: Percutaneous image-guided cryoneurolysis
CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
Visual Analog Scale (VAS) Improvement
Time frame: 12 weeks
Start is estimated for Nov 2023; primary completion for Nov 2026, 36 months later.
Of 34 observational studies under Pelvic Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.